word,tfidf
evaluate,0.4703176496465826
compare,0.24746820922791118
treatment,0.16909073129679553
effect,0.16061009240459517
gvhd,0.15884280818789887
week,0.15487401767585962
response,0.1434709235245538
survival,0.1434709235245538
relapse,0.1229750773067604
assess,0.12045756930344638
efficacy,0.12045756930344638
12,0.11785111575231204
days,0.10760319264341534
prophylaxis,0.10308332047048385
mammography,0.10189867438796343
incidence,0.09751327038850421
immune,0.09735526953451865
estimate,0.09664061294107862
objective,0.09019790541167338
overall,0.08710734642562194
tomosynthesis,0.08301375588718272
cells,0.0819833848711736
life,0.0819833848711736
disease,0.0819833848711736
change,0.08030504620229759
terms,0.08030504620229759
21,0.07731249035286289
rate,0.07685942331672524
quality,0.07685942331672524
synthetic,0.07471238029846444
free,0.07456897147356203
tumor,0.07456897147356203
cell,0.0717354617622769
safety,0.0717354617622769
biological,0.07086978282345766
100,0.0688328967448265
baseline,0.0688328967448265
uveitis,0.0688328967448265
failure,0.06661150020782855
group,0.06661150020782855
secondary,0.06661150020782855
primary,0.06661150020782855
objectives,0.06550629067797649
w55,0.06442707529405241
16,0.06309682201609096
compared,0.06309682201609096
activity,0.0614875386533802
grade,0.0614875386533802
inclusion,0.0614875386533802
24,0.0614875386533802
m6,0.05798436776464717
allogeneic,0.05736074728735542
adalimumab,0.05736074728735542
graft,0.05736074728735542
randomization,0.05636357709893185
arm,0.05636357709893185
msc,0.051624672558619876
regimen,0.051541660235241926
graall,0.051541660235241926
main,0.0512396155444835
acute,0.0512396155444835
remission,0.0512396155444835
transplant,0.0512396155444835
changes,0.05094933719398172
m12,0.05094933719398172
therapy,0.04611565399003515
severe,0.04611565399003515
analysis,0.04611565399003515
best,0.04611565399003515
mortality,0.04588859782988434
aiec,0.04588859782988434
reconstitution,0.04509895270583669
endoscopic,0.04509895270583669
profile,0.04509895270583669
nrm,0.04150687794359136
complete,0.0409916924355868
active,0.0409916924355868
post,0.0409916924355868
level,0.0409916924355868
tolerance,0.04015252310114879
hospitalization,0.04015252310114879
care,0.04015252310114879
tocilizumab,0.04015252310114879
m2,0.04015252310114879
m3,0.038656245176431445
versus,0.038656245176431445
cumulative,0.038656245176431445
worsening,0.038656245176431445
consolidation,0.03848048625470066
cryostem,0.03848048625470066
odv,0.03848048625470066
birads,0.03639238370998694
correlation,0.03639238370998694
prevalence,0.03639238370998694
progression,0.03586773088113845
10,0.03586773088113845
transplantation,0.03586773088113845
chronic,0.03586773088113845
treated,0.03586773088113845
behcets,0.03586773088113845
placebo,0.03586773088113845
risk,0.03586773088113845
partial,0.03441644837241325
2014,0.03441644837241325
function,0.03441644837241325
classification,0.03441644837241325
stage,0.03441644837241325
nk,0.03441644837241325
infusion,0.03441644837241325
metabolism,0.03320550235487309
irradiation,0.03320550235487309
anakinra,0.03320550235487309
ultrasound,0.03320550235487309
arms,0.032213537647026204
acuity,0.032213537647026204
corrected,0.032213537647026204
concentration,0.032213537647026204
os,0.032213537647026204
follow,0.0307437693266901
levels,0.0307437693266901
early,0.0307437693266901
benefit,0.0307437693266901
conditioning,0.0307437693266901
administration,0.0307437693266901
year,0.0307437693266901
ocular,0.0307437693266901
hydrocortisone,0.02911390696798955
host,0.02911390696798955
hhv8,0.02911390696798955
atlg,0.02911390696798955
m0,0.02911390696798955
markers,0.02911390696798955
keytruda,0.02911390696798955
superior,0.02911390696798955
atg,0.02911390696798955
monitored,0.02911390696798955
rbc,0.02911390696798955
simons,0.02911390696798955
plus,0.02911390696798955
fludrocortisone,0.02911390696798955
characterize,0.02911390696798955
cost,0.02911390696798955
28,0.02911390696798955
truly,0.02886036469102549
d14,0.02886036469102549
visual,0.02868037364367771
endpoint,0.02868037364367771
antibiotic,0.02868037364367771
obtained,0.02868037364367771
outcomes,0.02868037364367771
36,0.02868037364367771
term,0.02868037364367771
infectious,0.02868037364367771
index,0.02868037364367771
inflammation,0.02868037364367771
chamber,0.02868037364367771
factors,0.02868037364367771
sct,0.02868037364367771
adult,0.02868037364367771
ssc,0.02868037364367771
score,0.02868037364367771
engraftment,0.02868037364367771
effects,0.02868037364367771
cytokine,0.025770830117620963
500,0.025770830117620963
design,0.025770830117620963
demonstrate,0.025770830117620963
search,0.025770830117620963
mofetil,0.025770830117620963
mycophenolate,0.025770830117620963
analyses,0.025770830117620963
wbc,0.025770830117620963
180,0.025770830117620963
bcva,0.025770830117620963
improvement,0.025770830117620963
m1,0.025770830117620963
complications,0.02561980777224175
lesions,0.02561980777224175
groups,0.02561980777224175
refractory,0.02561980777224175
samples,0.02561980777224175
anterior,0.02561980777224175
outcome,0.02561980777224175
hsct,0.02561980777224175
total,0.02561980777224175
chimerism,0.02561980777224175
donor,0.02561980777224175
morbidity,0.024904126766154812
fecal,0.024904126766154812
inferior,0.024904126766154812
uc,0.024904126766154812
lineage,0.024904126766154812
infiltrate,0.024904126766154812
sle,0.02294429891494217
48,0.02294429891494217
pembrolizumab,0.02294429891494217
status,0.02294429891494217
laboratory,0.02294429891494217
isatuximab,0.02294429891494217
historical,0.02294429891494217
identical,0.02294429891494217
transfusion,0.02294429891494217
experimental,0.02294429891494217
characteristics,0.02294429891494217
different,0.02294429891494217
covid,0.02294429891494217
corticosteroids,0.02294429891494217
sf,0.021835430225992165
prognostic,0.021835430225992165
adherence,0.021835430225992165
rejection,0.021835430225992165
maintenance,0.021835430225992165
effectiveness,0.021835430225992165
extension,0.021835430225992165
40mg,0.021835430225992165
organs,0.021835430225992165
identify,0.021835430225992165
leakage,0.021835430225992165
pharmacodynamics,0.021835430225992165
iv,0.0204958462177934
60,0.0204958462177934
collection,0.0204958462177934
macular,0.0204958462177934
edema,0.0204958462177934
end,0.0204958462177934
assessed,0.0204958462177934
evolution,0.0204958462177934
treatments,0.0204958462177934
involvement,0.0204958462177934
plasma,0.0204958462177934
following,0.0204958462177934
haplo,0.0204958462177934
optimal,0.0204958462177934
19,0.0204958462177934
signs,0.0204958462177934
systemic,0.0204958462177934
probability,0.0204958462177934
steroid,0.0204958462177934
daily,0.0204958462177934
immunological,0.019328122588215722
hours,0.019328122588215722
twice,0.019328122588215722
impact,0.019328122588215722
initial,0.019328122588215722
kidney,0.019328122588215722
lymphocyte,0.019328122588215722
renal,0.019328122588215722
relative,0.019328122588215722
sarcoma,0.019328122588215722
expression,0.019328122588215722
laherparepvec,0.019328122588215722
allograft,0.019328122588215722
bone,0.019328122588215722
pan,0.019328122588215722
genetic,0.019328122588215722
80mg,0.019328122588215722
endemic,0.019328122588215722
clinically,0.019328122588215722
responders,0.019328122588215722
conventional,0.019328122588215722
ml,0.019328122588215722
talimogene,0.019328122588215722
pcr,0.019328122588215722
intermediate,0.019328122588215722
toxicities,0.019328122588215722
ph,0.019328122588215722
future,0.019328122588215722
needs,0.019328122588215722
composite,0.019328122588215722
comparatively,0.01924024312735033
cyp2d6,0.01924024312735033
cyp2c19,0.01924024312735033
specificity,0.01924024312735033
2g,0.01924024312735033
cognitive,0.01924024312735033
tcr,0.01924024312735033
explain,0.01924024312735033
modulation,0.01924024312735033
finding,0.01924024312735033
funding,0.01924024312735033
mucosal,0.01924024312735033
mrd1,0.01924024312735033
covariate,0.01924024312735033
signatures,0.01924024312735033
interactions,0.01924024312735033
antibiotics,0.017208224186206624
inflammatory,0.017208224186206624
overload,0.017208224186206624
occurrence,0.017208224186206624
central,0.017208224186206624
organ,0.017208224186206624
sparing,0.017208224186206624
serum,0.017208224186206624
major,0.017208224186206624
biopsies,0.017208224186206624
late,0.017208224186206624
classic,0.017208224186206624
appendix,0.017208224186206624
receiving,0.017208224186206624
requiring,0.017208224186206624
comparison,0.017208224186206624
criteria,0.017208224186206624
stem,0.017208224186206624
measure,0.017208224186206624
skin,0.017208224186206624
need,0.017208224186206624
iron,0.017208224186206624
month,0.017208224186206624
viral,0.017208224186206624
dysfunction,0.016602751177436544
w1,0.016602751177436544
immunophenotyping,0.016602751177436544
monocytes,0.016602751177436544
nelarabine,0.016602751177436544
transcriptomic,0.016602751177436544
censoring,0.016602751177436544
phenotype,0.016602751177436544
c2d1,0.016602751177436544
understand,0.016602751177436544
ig,0.016602751177436544
microbiota,0.016602751177436544
correlate,0.016602751177436544
w35,0.016602751177436544
w5,0.016602751177436544
household,0.016602751177436544
posterior,0.01537188466334505
increase,0.01537188466334505
anti,0.01537188466334505
weeks,0.01537188466334505
prca,0.01537188466334505
infections,0.01537188466334505
infection,0.01537188466334505
high,0.01537188466334505
retinal,0.01537188466334505
duration,0.01537188466334505
adverse,0.01537188466334505
associated,0.01537188466334505
step,0.01537188466334505
interval,0.01537188466334505
phase,0.01537188466334505
events,0.01537188466334505
30,0.01537188466334505
vitreous,0.01537188466334505
met,0.01537188466334505
vessel,0.01537188466334505
current,0.01537188466334505
additional,0.01537188466334505
load,0.014556953483994776
induction,0.014556953483994776
validate,0.014556953483994776
inferiority,0.014556953483994776
c4,0.014556953483994776
2005,0.014556953483994776
old,0.014556953483994776
tolerability,0.014556953483994776
orally,0.014556953483994776
prospectively,0.014556953483994776
quantification,0.014556953483994776
alloimmunization,0.014556953483994776
examinations,0.014556953483994776
comorbidity,0.014556953483994776
m9,0.014556953483994776
adults,0.014556953483994776
du,0.014556953483994776
sclerosis,0.014556953483994776
dfs,0.014556953483994776
diagnostic,0.014556953483994776
dependency,0.014556953483994776
cns,0.014556953483994776
complement,0.014556953483994776
base,0.014556953483994776
vs,0.014556953483994776
pharmacokinetics,0.014556953483994776
mrd,0.014556953483994776
platform,0.014556953483994776
intensive,0.014556953483994776
biology,0.014556953483994776
inactive,0.014556953483994776
profiles,0.014556953483994776
exploratory,0.014556953483994776
subcutaneously,0.014556953483994776
setting,0.012885415058810482
cycle,0.012885415058810482
cure,0.012885415058810482
correlated,0.012885415058810482
malignant,0.012885415058810482
role,0.012885415058810482
cd,0.012885415058810482
immunogenicity,0.012885415058810482
cr,0.012885415058810482
complementary,0.012885415058810482
underlying,0.012885415058810482
center,0.012885415058810482
hypothesis,0.012885415058810482
grfs,0.012885415058810482
global,0.012885415058810482
candidate,0.012885415058810482
allo,0.012885415058810482
lupus,0.012885415058810482
gene,0.012885415058810482
nervous,0.012885415058810482
niu,0.012885415058810482
mri,0.012885415058810482
oral,0.012885415058810482
dna,0.012885415058810482
better,0.012885415058810482
comparing,0.012885415058810482
mesylate,0.012885415058810482
chemotherapy,0.012885415058810482
sample,0.012885415058810482
scores,0.012885415058810482
lung,0.012885415058810482
determine,0.012885415058810482
vascular,0.011472149457471085
manifestations,0.011472149457471085
marrow,0.011472149457471085
cyclophosphamide,0.011472149457471085
mean,0.011472149457471085
confirmed,0.011472149457471085
collected,0.011472149457471085
allow,0.011472149457471085
responses,0.011472149457471085
evaluation,0.011472149457471085
endpoints,0.011472149457471085
reduction,0.011472149457471085
ratio,0.011472149457471085
regulatory,0.011472149457471085
received,0.011472149457471085
kaposi,0.011472149457471085
release,0.011472149457471085
prednisone,0.011472149457471085
points,0.011472149457471085
previous,0.011472149457471085
presence,0.011472149457471085
included,0.011472149457471085
line,0.011472149457471085
perform,0.011472149457471085
paris,0.011472149457471085
neutrophil,0.011472149457471085
liver,0.011472149457471085
radiation,0.011472149457471085
appropriate,0.011472149457471085
camostat,0.011472149457471085
inhibitor,0.011472149457471085
icu,0.011472149457471085
haze,0.011472149457471085
infusions,0.011472149457471085
therapies,0.011472149457471085
threatening,0.011472149457471085
parameters,0.011472149457471085
costs,0.011472149457471085
counts,0.011472149457471085
sensitivity,0.0102479231088967
order,0.0102479231088967
unrelated,0.0102479231088967
peripheral,0.0102479231088967
followed,0.0102479231088967
ii,0.0102479231088967
capmatinib,0.0102479231088967
40,0.0102479231088967
count,0.0102479231088967
considered,0.0102479231088967
cryoglobulinemia,0.0102479231088967
death,0.0102479231088967
specific,0.0102479231088967
resolution,0.0102479231088967
second,0.0102479231088967
severity,0.0102479231088967
event,0.0102479231088967
injection,0.0102479231088967
steroids,0.0102479231088967
toxicity,0.0102479231088967
previously,0.0102479231088967
eye,0.0102479231088967
corticosteroid,0.0102479231088967
assessment,0.0102479231088967
sections,0.009620121563675164
microbiological,0.009620121563675164
mirna,0.009620121563675164
mll,0.009620121563675164
supportive,0.009620121563675164
surrogacy,0.009620121563675164
want,0.009620121563675164
contacted,0.009620121563675164
broad,0.009620121563675164
haematopoietic,0.009620121563675164
ikzf1,0.009620121563675164
boost,0.009620121563675164
certain,0.009620121563675164
anas,0.009620121563675164
optimize,0.009620121563675164
ophthalmologic,0.009620121563675164
organized,0.009620121563675164
patterns,0.009620121563675164
pdl1,0.009620121563675164
pectoral,0.009620121563675164
pellets,0.009620121563675164
globule,0.009620121563675164
node,0.009620121563675164
notch1,0.009620121563675164
supervisor,0.009620121563675164
fbxw7,0.009620121563675164
nevous,0.009620121563675164
pm,0.009620121563675164
hermine,0.009620121563675164
stool,0.009620121563675164
strategies,0.009620121563675164
nutritional,0.009620121563675164
imagine,0.009620121563675164
fraall2000,0.009620121563675164
placebos,0.009620121563675164
potency,0.009620121563675164
cellular,0.009620121563675164
indices,0.009620121563675164
biocollection,0.009620121563675164
anomalies,0.009620121563675164
ago,0.009620121563675164
influence,0.009620121563675164
improves,0.009620121563675164
immunomonitoring,0.009620121563675164
omeprazole,0.009620121563675164
d28,0.009620121563675164
hydroxyomeprazole,0.009620121563675164
acquisition,0.009620121563675164
lymph,0.009620121563675164
production,0.009620121563675164
professor,0.009620121563675164
excellence,0.009620121563675164
exhaustion,0.009620121563675164
interrogating,0.009620121563675164
experiments,0.009620121563675164
iterative,0.009620121563675164
bioactivity,0.009620121563675164
phases,0.009620121563675164
biochemical,0.009620121563675164
intensification,0.009620121563675164
prevalance,0.009620121563675164
listed,0.009620121563675164
archival,0.009620121563675164
modifies,0.009620121563675164
intensified,0.009620121563675164
exploring,0.009620121563675164
kinetic,0.009620121563675164
mediator,0.009620121563675164
biomarker,0.009620121563675164
montparnasse,0.009620121563675164
amplified,0.009620121563675164
assays,0.009620121563675164
bio,0.009620121563675164
multicentricity,0.009620121563675164
ras,0.009620121563675164
pump,0.009620121563675164
pten,0.009620121563675164
provisional,0.009620121563675164
proton,0.009620121563675164
alloreactivity,0.009620121563675164
mrna,0.009620121563675164
rouge,0.009620121563675164
rating,0.009620121563675164
programme,0.009620121563675164
transport,0.009620121563675164
efferocytosis,0.009620121563675164
elaborate,0.009620121563675164
reproducibility,0.009620121563675164
bilirubine,0.009620121563675164
lpf,0.009620121563675164
kind,0.009620121563675164
reinforced,0.009620121563675164
repercussions,0.009620121563675164
rehospitalizations,0.009620121563675164
d42,0.009620121563675164
quantified,0.009620121563675164
eradicated,0.009620121563675164
diffuse,0.009620121563675164
cyp3a4,0.009620121563675164
75015,0.009620121563675164
signature,0.009620121563675164
signals,0.009620121563675164
belgium,0.009620121563675164
banked,0.009620121563675164
mast,0.009620121563675164
variations,0.009620121563675164
variability,0.009620121563675164
2d6,0.009620121563675164
4th,0.009620121563675164
100mg,0.009620121563675164
views,0.009620121563675164
16s,0.009620121563675164
162mg,0.009620121563675164
150mg,0.008301375588718272
vellefaux,0.008301375588718272
vh,0.008301375588718272
56,0.008301375588718272
vod,0.008301375588718272
2x106,0.008301375588718272
365,0.008301375588718272
sf36,0.008301375588718272
schemes,0.008301375588718272
claude,0.008301375588718272
analyse,0.008301375588718272
mra,0.008301375588718272
avenue,0.008301375588718272
mcr,0.008301375588718272
cytometry,0.008301375588718272
d100,0.008301375588718272
screened,0.008301375588718272
specimens,0.008301375588718272
stages,0.008301375588718272
d7,0.008301375588718272
dendritic,0.008301375588718272
cy,0.008301375588718272
concurrent,0.008301375588718272
ae,0.008301375588718272
75475,0.008301375588718272
80c,0.008301375588718272
respective,0.008301375588718272
laboratoire,0.008301375588718272
muscular,0.008301375588718272
native,0.008301375588718272
necker,0.008301375588718272
ll03,0.008301375588718272
kaposis,0.008301375588718272
disability,0.008301375588718272
routine,0.008301375588718272
rennes,0.008301375588718272
enterobacteriaceae,0.008301375588718272
erythematosus,0.008301375588718272
evaluating,0.008301375588718272
dry,0.008301375588718272
collections,0.008301375588718272
randomly,0.008301375588718272
reached,0.008301375588718272
protocols,0.008301375588718272
ex,0.008301375588718272
inspired,0.008301375588718272
negativation,0.008301375588718272
normalization,0.008301375588718272
alteration,0.008301375588718272
alterations,0.008301375588718272
pyelonephritis,0.008301375588718272
cardio,0.008301375588718272
tract,0.008301375588718272
prognosis,0.008301375588718272
feasibility,0.008301375588718272
chu,0.008301375588718272
precision,0.008301375588718272
phenotypes,0.008301375588718272
gastrointestinal,0.008301375588718272
glucose,0.008301375588718272
gonadic,0.008301375588718272
gp,0.008301375588718272
graall2003,0.008301375588718272
pancreatitis,0.008301375588718272
olivier,0.008301375588718272
opioids,0.008301375588718272
immuno,0.008301375588718272
immunologic,0.008301375588718272
immunomodulation,0.008301375588718272
caecum,0.008301375588718272
pk,0.008301375588718272
grcs,0.008301375588718272
hemagglutinins,0.008301375588718272
ancillary,0.008301375588718272
aimed,0.008301375588718272
org,0.008301375588718272
tnfa,0.008301375588718272
hrqol,0.008301375588718272
hematologic,0.008301375588718272
tumour,0.008301375588718272
gastrectomy,0.008301375588718272
supervision,0.008301375588718272
pbmc,0.008301375588718272
boulevard,0.008301375588718272
brands,0.008301375588718272
bvas,0.008301375588718272
24h,0.008301375588718272
42,0.008301375588718272
48h,0.008301375588718272
slicc,0.008301375588718272
sodium,0.008301375588718272
sepsis,0.008301375588718272
continued,0.008301375588718272
d21,0.008301375588718272
switzerland,0.008301375588718272
siti,0.008301375588718272
situation,0.008301375588718272
ac,0.008301375588718272
acr,0.007278476741997388
tarte,0.007278476741997388
surgical,0.007278476741997388
metabolic,0.007278476741997388
mmf,0.007278476741997388
ch50,0.007278476741997388
breast,0.007278476741997388
c3,0.007278476741997388
social,0.007278476741997388
controls,0.007278476741997388
autoantibodies,0.007278476741997388
improve,0.007278476741997388
fresh,0.007278476741997388
graaph,0.007278476741997388
persistent,0.007278476741997388
fertility,0.007278476741997388
infiltration,0.007278476741997388
cervical,0.007278476741997388
hospitalisation,0.007278476741997388
allocated,0.007278476741997388
affected,0.007278476741997388
undergoing,0.007278476741997388
hr,0.007278476741997388
immunotherapy,0.007278476741997388
participate,0.007278476741997388
pediatric,0.007278476741997388
analyze,0.007278476741997388
gammaglobulin,0.007278476741997388
inform,0.007278476741997388
stored,0.007278476741997388
storage,0.007278476741997388
sub,0.007278476741997388
subgroups,0.007278476741997388
immunomodulatory,0.007278476741997388
optimized,0.007278476741997388
phenotyping,0.007278476741997388
success,0.007278476741997388
subpopulation,0.007278476741997388
anxiety,0.007278476741997388
rifaximin,0.007278476741997388
colon,0.007278476741997388
comparative,0.007278476741997388
rheumatoid,0.007278476741997388
proteinuria,0.007278476741997388
radiotherapy,0.007278476741997388
rank,0.007278476741997388
reactants,0.007278476741997388
eq5d,0.007278476741997388
equivalent,0.007278476741997388
eradication,0.007278476741997388
estimation,0.007278476741997388
recurrence,0.007278476741997388
charlson,0.007278476741997388
chelation,0.007278476741997388
check,0.007278476741997388
efs,0.007278476741997388
resistant,0.007278476741997388
recently,0.007278476741997388
recipients,0.007278476741997388
d60,0.007278476741997388
colonized,0.007278476741997388
actg,0.007278476741997388
intravenous,0.007278476741997388
length,0.007278476741997388
mscs,0.007278476741997388
intensity,0.007278476741997388
ptcy,0.007278476741997388
cd20,0.007278476741997388
cd19,0.007278476741997388
circulating,0.007278476741997388
ciprofloxacin,0.007278476741997388
priapism,0.007278476741997388
transmission,0.007278476741997388
frozen,0.007278476741997388
functional,0.007278476741997388
250,0.007278476741997388
vasopressors,0.007278476741997388
condition,0.007278476741997388
conduct,0.007278476741997388
m15,0.007278476741997388
lymphoma,0.007278476741997388
m24,0.007278476741997388
auc,0.007278476741997388
ctc,0.007278476741997388
criss,0.007278476741997388
serological,0.007278476741997388
sequential,0.007278476741997388
sight,0.007278476741997388
scd,0.007278476741997388
sri,0.007278476741997388
spontaneous,0.007278476741997388
conclusion,0.007278476741997388
derived,0.007278476741997388
59,0.007278476741997388
stenosis,0.007278476741997388
state,0.007278476741997388
determination,0.007278476741997388
lead,0.007278476741997388
detection,0.007278476741997388
myeloablative,0.007278476741997388
necrosis,0.007278476741997388
lines,0.007278476741997388
molecular,0.007278476741997388
logmar,0.007278476741997388
diagnosed,0.007278476741997388
dl,0.007278476741997388
d29,0.007278476741997388
bilag,0.007278476741997388
monotherapy,0.007278476741997388
antidepressant,0.007278476741997388
silent,0.006442707529405241
surface,0.006442707529405241
www,0.006442707529405241
achieved,0.006442707529405241
acs,0.006442707529405241
overlap,0.006442707529405241
formula,0.006442707529405241
gr,0.006442707529405241
hgf,0.006442707529405241
stroke,0.006442707529405241
infliximab,0.006442707529405241
infarct,0.006442707529405241
induced,0.006442707529405241
creatinine,0.006442707529405241
cerebral,0.006442707529405241
analyzed,0.006442707529405241
hemolytic,0.006442707529405241
2003,0.006442707529405241
cov,0.006442707529405241
context,0.006442707529405241
selena,0.006442707529405241
aged,0.006442707529405241
sledai,0.006442707529405241
immunosuppressive,0.006442707529405241
usually,0.006442707529405241
grafalon,0.006442707529405241
thymoglobulin,0.006442707529405241
hopital,0.006442707529405241
mismatch,0.006442707529405241
extra,0.006442707529405241
eyes,0.006442707529405241
fact,0.006442707529405241
fish,0.006442707529405241
person,0.006442707529405241
chosen,0.006442707529405241
phenotypic,0.006442707529405241
pfs,0.006442707529405241
treosulfan,0.006442707529405241
examination,0.006442707529405241
bleeding,0.006442707529405241
blinded,0.006442707529405241
real,0.006442707529405241
erythrocyte,0.006442707529405241
ref,0.006442707529405241
reduced,0.006442707529405241
activation,0.006442707529405241
qol,0.006442707529405241
causes,0.006442707529405241
fludarabine,0.006442707529405241
point,0.006442707529405241
aml,0.006442707529405241
allows,0.006442707529405241
bmt,0.006442707529405241
biomarkers,0.006442707529405241
biopsy,0.006442707529405241
negative,0.006442707529405241
initiation,0.006442707529405241
institut,0.006442707529405241
interim,0.006442707529405241
functions,0.006442707529405241
procedures,0.006442707529405241
relapses,0.006442707529405241
replacement,0.006442707529405241
receive,0.006442707529405241
transplanted,0.006442707529405241
aa,0.006442707529405241
abo,0.006442707529405241
damage,0.006442707529405241
adequate,0.006442707529405241
detected,0.006442707529405241
mmol,0.006442707529405241
moderate,0.006442707529405241
directly,0.006442707529405241
like,0.006442707529405241
mud,0.006442707529405241
respiratory,0.006442707529405241
cutaneous,0.006442707529405241
stay,0.006442707529405241
depression,0.006442707529405241
cytokines,0.006442707529405241
association,0.006442707529405241
mechanical,0.006442707529405241
screening,0.006442707529405241
measurement,0.006442707529405241
lymphocytes,0.006442707529405241
clearance,0.006442707529405241
cohorts,0.006442707529405241
consumption,0.006442707529405241
saint,0.006442707529405241
ventilation,0.006442707529405241
voc,0.006442707529405241
virological,0.006442707529405241
05,0.006442707529405241
18,0.005736074728735542
withdrawal,0.005736074728735542
single,0.005736074728735542
start,0.005736074728735542
size,0.005736074728735542
source,0.005736074728735542
scale,0.005736074728735542
starting,0.005736074728735542
spartalizumab,0.005736074728735542
right,0.005736074728735542
review,0.005736074728735542
surgery,0.005736074728735542
support,0.005736074728735542
residual,0.005736074728735542
reduce,0.005736074728735542
proportion,0.005736074728735542
plan,0.005736074728735542
population,0.005736074728735542
platelet,0.005736074728735542
percentage,0.005736074728735542
pr,0.005736074728735542
symptoms,0.005736074728735542
monitoring,0.005736074728735542
neurological,0.005736074728735542
notably,0.005736074728735542
obtain,0.005736074728735542
performance,0.005736074728735542
syndromes,0.005736074728735542
hla,0.005736074728735542
hospital,0.005736074728735542
hospitalizations,0.005736074728735542
having,0.005736074728735542
follows,0.005736074728735542
thrombosis,0.005736074728735542
https,0.005736074728735542
therapeutic,0.005736074728735542
iii,0.005736074728735542
low,0.005736074728735542
injected,0.005736074728735542
louis,0.005736074728735542
long,0.005736074728735542
mds,0.005736074728735542
matched,0.005736074728735542
33,0.005736074728735542
visit,0.005736074728735542
absence,0.005736074728735542
able,0.005736074728735542
anemia,0.005736074728735542
belimumab,0.005736074728735542
bd,0.005736074728735542
body,0.005736074728735542
antibodies,0.005736074728735542
approach,0.005736074728735542
type,0.005736074728735542
course,0.005736074728735542
delayed,0.005736074728735542
cycles,0.005736074728735542
exposure,0.005736074728735542
ileal,0.005736074728735542
flow,0.005736074728735542
factor,0.005736074728735542
transfusions,0.005736074728735542
frequency,0.005736074728735542
good,0.005736074728735542
heart,0.005736074728735542
uninjected,0.005736074728735542
unit,0.005736074728735542
considering,0.005736074728735542
committee,0.005736074728735542
calculated,0.005736074728735542
exposed,0.005736074728735542
poor,0.00512396155444835
sars,0.00512396155444835
20,0.00512396155444835
recommendations,0.00512396155444835
syndrome,0.00512396155444835
measures,0.00512396155444835
medical,0.00512396155444835
mg,0.00512396155444835
observed,0.00512396155444835
period,0.00512396155444835
model,0.00512396155444835
pre,0.00512396155444835
rates,0.00512396155444835
procedure,0.00512396155444835
reported,0.00512396155444835
management,0.00512396155444835
kg,0.00512396155444835
independent,0.00512396155444835
increased,0.00512396155444835
tnf,0.00512396155444835
france,0.00512396155444835
hematopoietic,0.00512396155444835
greater,0.00512396155444835
health,0.00512396155444835
test,0.00512396155444835
evidence,0.00512396155444835
doses,0.00512396155444835
data,0.00512396155444835
validated,0.00512396155444835
cardiac,0.00512396155444835
adapted,0.00512396155444835
amplification,0.00512396155444835
70,0.00512396155444835
50,0.00512396155444835
value,0.00512396155444835
vasculitis,0.00512396155444835
